Prognostic value of Akt-1 in human prostate cancer: A computerized quantitative assessment with quantum dot technology

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3568-3573

  Li, Rile ^a   Dai, Hong ^a   Wheeler, Thomas M ^a   Sayeeduddin, Mohammad ^a   Scardino, Peter T ^b   Frolov, Anna ^a   Ayala, Gustavo E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; PROTEIN KINASE B; QUANTUM DOT; STREPTAVIDIN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER MORTALITY; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA BASE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TECHNOLOGY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; QUANTUM DOTS; TISSUE ARRAY ANALYSIS;

EID: 66149164440     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0826     Document Type: Article

References (22)

1. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-887 (Pubitemid 40461690)
2. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-118 (Pubitemid 43118073)
3. Nakatani K, Thompson DA, Barthel A, et al. Upregulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-21532 (Pubitemid 129519688)
4. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003;9:5271-5281 (Pubitemid 37413579)
5. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006;94:1906-1912 (Pubitemid 43882583)
6. Liao Y, Grobholz R, Abel U, et al. Increase of AKT/PKB expression correlates with Gleason pattern in human prostate cancer. Int J Cancer 2003;107:676-680 (Pubitemid 37296133)
7. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-6578 (Pubitemid 39346553)
8. 473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-5236
9. Stern DF. More than a marker...phosphorylated Akt in prostate carcinoma. Clin Cancer Res 2004;10:6407-6410 (Pubitemid 39346534)
10. Liao Z, Wang S, Boileau TW, Erdman JW, Jr., Clinton SK. Increased phospho-AKT is associated with loss of the androgen receptor during the progression of N-methyl-N-nitrosourea-induced prostate carcinogenesis in rats. Prostate 2005;64:186-199 (Pubitemid 40791768)
11. Chadha KS, Khoury T, Yu J, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006;13:933-939 (Pubitemid 43920925)
12. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer (Amsterdam, Netherlands) 2006;51:181-191 (Pubitemid 43144361)
13. Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005;14:389-392
14. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer (Tokyo, Japan) 2006;13:137-144
15. Ghazani AA, Lee JA, Klostranec J, et al. High throughput quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett 2006;6:2881-2886 (Pubitemid 46129588)
16. Witkiewicz AK, Varambally S, Shen R, et al. α-Methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1418-1423 (Pubitemid 40807340)
17. Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994;25:274-279 (Pubitemid 24364132)
18. Dai H, Li R, Wheeler T, et al. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 2005;65:276-286 (Pubitemid 41443733)
19. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003;310:1124-1132 (Pubitemid 37237653)
20. Li Y, Sarkar FH. Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-2377 (Pubitemid 34753612)
21. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003;28:145-153
22. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-24505 (Pubitemid 30626543)